A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: a study protocol for the Tina Trial

Abstract Background There are no approved pharmacotherapies for methamphetamine use disorder. Two preliminary phase 2 randomised controlled trials have found mirtazapine, a tetracyclic antidepressant, to be effective in reducing methamphetamine use. The proposed Tina Trial is the first phase 3 place...

詳細記述

書誌詳細

主要な著者:	Rebecca McKetin, Tayla J. Degan, Lucy Saunders, Long Nguyen, Gregory Dore, Steven Shoptaw, Michael Farrell, Louisa Degenhardt, Peter J. Kelly, Alyna Turner, Philip J. Clare, Olivia M. Dean, Shalini Arunogiri, Samantha Colledge-Frisby, Juanita Koeijers, David Goodman-Meza, Barbara Sinclair, David Reid, Harry Hill, Jeremy Hayllar, Michael Christmass, Frank Cordaro, Robert Lundin, Willy Liaw, Danica Liu, Ellie Holyoak, Brian Tid-Fung Wu, Joel Keygan, Ava Kontogiannis, Lily Palmer, Caity Morrison, Anna Wrobel, Bec Hyland, Marianne Byrne, Samantha Russell, Emma Zahra, Michael Berk
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMC 2024-06-01
シリーズ:	Trials
主題:	Substance use disorders Methamphetamine Mirtazapine Clinical trial Depression Sleep
オンライン･アクセス:	https://doi.org/10.1186/s13063-024-08238-y
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!